TRIP4

TRIP4 is a multifunctional scaffolding protein that operates both as the core subunit of the tetrameric ASC-1 (ASCC) complex in ribosome-associated quality control and translation initiation, and as a sequence-independent DNA-binding transcriptional coactivator at specific gene promoters. Within the ASCC complex, TRIP4 participates in ATP-dependent disassembly of collided (stalled) ribosomes downstream of ZNF598-mediated 40S ubiquitination and in promoting translation initiation at 5′ UTRs of a subset of mRNAs via association with scanning 43S preinitiation complexes (PMID:32579943, PMID:37092320). The C-terminal ASCH domain of TRIP4 binds single- and double-stranded DNA in a sequence-independent manner through two positively charged surface patches, and TRIP4 directly occupies the promoters of target genes including PAI-2, DDIT4, COX-2, iNOS, and GATA2 to activate their transcription, in some cases synergizing with p300 (PMID:38870938, PMID:19074642, PMID:34648907, PMID:28899685, PMID:40180167). TRIP4 also modulates NF-κB signaling through its interaction with p65, which is disrupted by RNF25-mediated non-degradative ubiquitination at K135, and regulates cell cycle progression and myotube growth in skeletal muscle (PMID:40765826, PMID:31794073, PMID:27008887).

1. 2008 Medium

   Establishing TRIP4 as a promoter-binding transcriptional coactivator: the ASC-1 complex was shown to bind a specific response element in the PAI-2 promoter and mediate gastrin-induced transcription, demonstrating that TRIP4 functions directly at gene promoters rather than solely as a nuclear receptor coactivator.

   Evidence Yeast one-hybrid screening, promoter mutational analysis, RNAi knockdown, and reporter assays in gastric cells

   PMID:19074642

   Open questions at the time

   • Single target gene; generalizability of promoter-binding was unknown
   • Mechanism of TRIP4 recruitment to specific promoter elements not defined
   • Contribution of individual ASC-1 subunits to DNA binding not resolved
2. 2016 High

   Linking TRIP4 to muscle cell differentiation: TRIP4 depletion reduced myotube diameter without affecting fusion or early differentiation, establishing a specific role for TRIP4 in late myogenic differentiation and myotube growth.

   Evidence shRNA knockdown in C2C12 and patient-derived muscle cells with myotube morphometry

   PMID:27008887

   Open questions at the time

   • Transcriptional targets mediating the myotube growth phenotype not identified
   • Whether the ASCC complex or TRIP4 alone drives this function was unclear
3. 2017 Medium

   Demonstrating TRIP4 occupancy at inflammatory gene promoters: ChIP showed TRIP4 directly anchors at COX-2 and iNOS promoters in synergy with p300, linking TRIP4 transcriptional coactivation to NF-κB-dependent gene expression in melanoma.

   Evidence ChIP assay, Co-IP with p300, siRNA knockdown, and xenograft models in melanoma cells

   PMID:28899685

   Open questions at the time

   • Whether TRIP4 contacts DNA directly or is recruited via p300/other factors was unresolved
   • Structural basis for promoter selectivity unknown
4. 2018 High

   Connecting the ASC-1 complex to the RNAP II/U1 snRNP machinery: all four ALS-causative RNA/DNA-binding proteins were required for ASC-1 association with RNAP II, and disease mutations disrupted this interaction, placing TRIP4 at the intersection of transcription and neurodegenerative disease pathways.

   Evidence CRISPR knockout, mass spectrometry interactome, and reciprocal Co-IP in human cells

   PMID:30398641

   Open questions at the time

   • Functional consequence of lost RNAP II association on specific transcripts not determined
   • Direct versus indirect bridging by ALS proteins not resolved
5. 2019 High

   Identifying TRIP4 as a cell cycle regulator: TRIP4 depletion shortened G0/G1, accelerated proliferation, and reduced cell size, revealing a function in cell cycle control distinct from its transcriptional coactivation of specific genes.

   Evidence FACS cell cycle analysis and Western blot for cell cycle proteins in C2C12 and patient-derived cells

   PMID:31794073

   Open questions at the time

   • Direct transcriptional targets responsible for cell cycle phenotype not identified
   • Whether the effect is ASC-1 complex-dependent or TRIP4-autonomous was unknown
6. 2020 High

   Revealing the ribosome quality control function of the ASCC complex: reconstitution showed that the ASCC complex, with TRIP4 as a subunit, disassembles the leading stalled ribosome in collided polysomes in an ATP-dependent, ZNF598-ubiquitination-dependent manner, establishing a mechanistically distinct pathway from canonical ribosome recycling.

   Evidence Mammalian cell-free reconstitution of collided polysome disassembly with biochemical fractionation and dominant-negative experiments

   PMID:32579943

   Open questions at the time

   • Specific role of TRIP4 within the ASCC complex during ribosome splitting not defined
   • Whether TRIP4's DNA-binding domain contributes to ribosome recognition was untested
7. 2021 Medium

   Expanding the transcriptional target repertoire: TRIP4 was shown to directly bind the DDIT4 promoter and activate its transcription, connecting TRIP4 to mTOR signaling regulation in glioma under HIF1α influence.

   Evidence ChIP assay, promoter deletion reporters, siRNA knockdown with rescue, and xenograft in glioma cells

   PMID:34648907

   Open questions at the time

   • Mechanism by which HIF1α influences TRIP4 activity at the DDIT4 promoter not resolved
   • Single cancer type studied
8. 2024 High

   Solving the structural basis for TRIP4 DNA binding: the crystal structure of the ASCH domain revealed sequence-independent ssDNA and dsDNA binding via two positively charged patches contacting the 5′ and 3′ ends of DNA, providing a molecular explanation for TRIP4's ability to occupy diverse promoters.

   Evidence Crystal structure determination, biochemical binding assays, and site-directed mutagenesis

   PMID:38870938

   Open questions at the time

   • How sequence-independent DNA binding achieves promoter specificity in vivo remains unresolved
   • No structure of TRIP4 in complex with other ASCC subunits or transcriptional machinery
9. 2025 Medium

   Defining post-translational regulation of TRIP4: RNF25-mediated non-degradative ubiquitination at K135 disrupts the TRIP4–p65 interaction, liberating p65 to activate NF-κB target genes, revealing how TRIP4 is regulated to modulate inflammatory signaling.

   Evidence Co-IP, K135 site-directed mutagenesis, and functional rescue experiments in renal cell carcinoma cells

   PMID:40765826

   Open questions at the time

   • Whether K135 ubiquitination affects TRIP4's ribosome quality control function untested
   • Deubiquitinase reversing this modification not identified
10. 2025 Medium

    Adding GATA2 as a direct TRIP4 transcriptional target: TRIP4 binds the GATA2 promoter and activates its transcription in cervical cancer, with GATA2 overexpression rescuing TRIP4 knockdown effects on growth and radiation sensitivity.

    Evidence ChIP, pulldown, RNA-seq of knockdown cells, and rescue experiments

    PMID:40180167

    Open questions at the time

    • TRIP4's promoter selectivity mechanism still unresolved despite known DNA-binding structure
    • Whether GATA2 regulation occurs in non-cancer contexts untested

• The specific molecular role of TRIP4 within the ASCC complex during ribosome splitting — whether it serves as a structural scaffold, contacts the ribosome directly, or modulates ASCC3 helicase activity — remains mechanistically undefined, as does the question of how TRIP4 partitions between its ribosome quality control and transcriptional coactivation functions.
• No structure of TRIP4 within the assembled ASCC complex on ribosomes
• No separation-of-function mutations distinguishing translational from transcriptional roles
• How TRIP4's sequence-independent DNA binding achieves promoter selectivity in vivo is unresolved